NCT01192568 - Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2011

Primary Completion Date

August 29, 2023

Study Completion Date

October 24, 2023

Conditions

Overactive DetrusorNeurogenic Bladder

Interventions

DRUG

Oxybutynin

10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.

DRUG

Placebo

Topical gel

Trial Locations (10)

Albany Medical College /ID# 236880, Albany

Child Hosp of the King's Dtr's /ID# 237799, Norfolk

Duke University /ID# 237494, Durham

Cook Children's Med. Center /ID# 237538, Fort Worth

Children's Hospital Colorado - Aurora /ID# 237620, Aurora

Loma Linda University /ID# 236889, Loma Linda

Child Hosp of Orange County,CA /ID# 237517, Orange

Augusta University Medical Center /ID# 238188, Augusta

University of Mississippi Medical Center /ID# 238065, Jackson

Duplicate_Oregon Health & Science University /ID# 234354, Portland